Loading data for XFOR — first visit, this takes a few seconds.

アラート

X4 Pharmaceuticals Inc. (XFOR)

NasdaqCM: XFOR · リアルタイム株価 · USD

4.20

-0.01 (-0.24%)

終値時点： Aug 19, 2026, 3:20 PM

-0.24% (1D)

データがありません

買気配	3.08
時価総額	418.89M
売上高（TTM）	15.85M
純利益（TTM）	-90.14M
ベータ	0.39
EPS（TTM）	1.43
PER（TTM）	2.95
予想PER	-5.6
PBR（TTM）	2.61
PSR（TTM）	26.43
Earnings Date	Nov 5, 2026

売気配	5.4
出来高	184,249
平均出来高（20日）	750,170
始値	4.25
前日終値	4.21
当日レンジ	4.20 - 4.35
52週レンジ	2.69 - 4.83
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

XFORについて

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agre...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Nov 16, 2017

従業員数 45

上場取引所 NasdaqCM

ティッカー XFOR

ウェブサイト https://www.x4pharma.com

企業情報の全文

業績

2025年のX4 Pharmaceuticalsの売上高は35.11Mで、前年の2.56Mから1,273.21%の増加でした。利益は-79.2Mで、111.48%の増加でした。

財務諸表

決算サプライズ

X4 PharmaceuticalsはAug 6, 2026に四半期決算を発表しました：

売上高は $8.81M で、予想を下回りました $0, うち 346.33% の前年比増加にあたります.

EPSは -0.13 で、予想を上回りました 0.05, うち 96.25% の前年比増加にあたります.

次回決算発表

X4 Pharmaceuticals Inc.の決算発表予定日は Nov 5, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1週間前 · Zacks

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1週間前 · Zacks

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3か月前 · Simply Wall St.

How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress

X4 Pharmaceuticals has seen its modeled fair value price target move from US$8.00 to US$11.67, a sizable uplift that puts more focus on what the current share price is really discounting. Analysts are...

3か月前 · Zacks

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could...

3か月前 · Zacks

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2ページ中1ページ

X4 Pharmaceuticals Inc. (XFOR)